DelveInsight’s Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Knee Osteoarthritis market report provides current treatment practices, emerging drugs, Knee Osteoarthritis market share of the individual therapies, and current and forecasted Knee Osteoarthritis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Knee Osteoarthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Knee Osteoarthritis market.
Some of the key facts of the Knee Osteoarthritis Market:
- As per the analysis, a higher percentage of mild cases of knee OA was observed in the 7MM, followed by moderate knee OA in 2021. In the US, mild knee OA accounted for the highest cases in 2021, followed by moderate knee OA with 7,373,858 and 6,562,734, respectively.
- In EU5, in 2021, the highest proportion of age-specific cases was observed in 70 years and above, followed by age groups of 60–69 years and 50–59 years. In 2021, there were 638,280, 1,735,323, 4,328,335, 4,807,045 and 8,437,262 cases, in the age groups 18–39 years, 40–49 years, 50–59 years, and 60–69 years and 70 years and above, respectively.
- Japan accounted for 10,267,932 prevalent symptomatic Knee OA cases in 2021. Among these cases, the prevalent knee OA cases were 4,312,531 in males and 6,407,189 in females in 2021.
Got queries? Click here to know more about the Knee Osteoarthritis Market Landscape
Knee Osteoarthritis Overview
·Knee osteoarthritis (OA), also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage. It is most common in the elderly and can be divided into two types, primary and secondary. Primary osteoarthritis is articular degeneration without any apparent underlying reason. Secondary osteoarthritis is the consequence of either an abnormal concentration of force across the joint as with post-traumatic causes or abnormal articular cartilage, such as rheumatoid arthritis (RA). The symptoms of knee OA usually develop gradually. This is because it takes time for the cartilage to wear down and change the way your joints work. However, sudden onset of symptoms is possible—but not as common. Knee symptoms can vary depending on the cause of the problem. The most common symptom of knee OA is pain around the knee joint. Pain can be dull, sharp, constant, or intermittent (off and on). Pain can vary from mild to agonizing.·Knee OA affects the three compartments of the knee joint (medial, lateral, and patellofemoral joint) and usually develops slowly over 10–15 years, interfering with daily life activities.
Knee Osteoarthritis Epidemiological Insight:
- The Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study in Japan showed a significant rise in knee OA through working age. As per this study, in Japan, OA affects approximately 25.3 million individuals aged over 40 years. Knee pain was a common symptom in the ROAD study, observed in approximately half the patients with radiographic knee OA, with a prevalence of 5.0% in men and 11.3% in women aged 40 years and older (Yoshimura, 2011).
- The study by Swain et al. (2020) aimed to explore the incidence and prevalence of OA in the UK in 2017 and their trends from 1997 to 2017 using the UK Clinical Practice Research Data link (CPRD) comprising data on nearly 17.5 million patients. The study showed that 10% of adults in the UK had been clinically diagnosed with OA. The study observed a trend that the total number of cases of OA in the UK had increased over the years, as the total prevalence of patients with any type of OA increased to 10.7% in 2017 from 8.2% in 1998, a 1.3-fold rise in prevalence. For any OA, the average yearly percentage change was 1.4% since 1998. This study confirmed a high burden of OA in the UK.
- According to the finding of the Knee and Hip Osteoarthritis Long-term Assessment (KHOALA) cohort study by Francis Guillemin et al. (2012), as per the Kellgren and Lawrence (KL) classification for stratifying disease severity, 44.5% of patients with symptomatic knee OA had Grade 2 severity, while 30.3% and 25.2% of patients with symptomatic knee OA had Grade 3 and Grade 4 severity, respectively.
Knee Osteoarthritis Epidemiological Segmentation
- Knee Osteoarthritis prevalent population
- Knee Osteoarthritis severity-specific prevalence
- Knee Osteoarthritis gender-specific distribution
- Knee Osteoarthritis age-specific distribution
Knee Osteoarthritis Market Outlook
The Knee Osteoarthritis market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Knee Osteoarthritis market trends by analyzing the impact of current Knee Osteoarthritis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Knee Osteoarthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Knee Osteoarthritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Knee Osteoarthritis market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @Knee Osteoarthritis Market Landscape
Knee Osteoarthritis Key Companies
- Centrexion Therapeutics
- Taiwan Liposome Company
- Sorrento Therapeutics/ Grünenthal GmbH
- Biosplice Therapeutics
- Techfields Pharma
- Regeneron Pharmaceutical
- And many more
Knee Osteoarthritis Key Therapies
- CNTX-497
- TLC599
- Resiniferatoxin
- Lorecivivint
- X0002
- Fasinumab
- And many more
Market Drivers
- Robust emerging pipeline
- Upsurge in the geriatric population
- Increased use of hyaluronic acid
- Novel therapeutic agent
Market Barriers
- Drug misuse and addiction
- Lack of reimbursement policies for Knee OA
- Dominance of existing therapies for symptomatic knee OA
- Large market share of over-the-counter medicine (OTC)
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Knee Osteoarthritis Market
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Market Drivers
- Market Barriers
- Knee Osteoarthritis Market Emerging Therapies
- Knee Osteoarthritis Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Knee Osteoarthritis Market Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Knee Osteoarthritis Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com